Company
CNSX:MVMD
Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCMKTS:MVMD) is building a world-class biotech and life sciences company centered around the implementation of its patented Quicksome oral drug formulation and delivery technologies. The company applies its Quicksome desiccation technology towards the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep and anxiety. It is also looking at the fight against the coronavirus (COVID-19). Quicksome enables unprecedented delivery impact through sublingual and buccal formats that provide direct absorption into the bloodstream, dramatically improving drug efficacy, dosing and end-user experience. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. The Quicksome technology has been in development since 2010, and initially incorporated into several commercial dietary supplement products. To date, the company has 14 patents in its portfolio, 12 extensions and has filed over a dozen provisional patents with respect to its Quicksome technology.
42 stories · page 2 of 3
The World Health Organization (WHO) estimates that more than 50% of vaccines are wasted globally every year due to temperature control and logistics
Dennis Hancock, Mountain Valley MD CEO, said the patent would allow the group "to move forward in securing the global protections necessary across many human and animal health applications without competitive interference"
The BSL-4 study was the first of its kind ever conducted with human grade solubilized Ivermectin in the world
The Canadian company is focused on the implementation of its patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology
The company is focused on the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep and anxiety
The company said the cancer patent has been filed for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens
The company said ivectosol is being tested to target certain cancers to pursue novel human intratumoral injection and intravenous infusion
The biotechnology company’s board of directors has approved the move
The company is finalizing production supply agreements with Bangladeshi pharmaceutical partners to produce Ivectosol 1% for use and distribution throughout the country
Selamectin was once considered a water-insoluble molecule but with tremendous potential in treating parasitic infestations in husbandry and companion animals as well as buruli ulcer, leprosy, and tuberculosis in humans
Mountain Valley MD told investors that it believes the 505(b)(2) pathway will result in a much less expensive and much faster route to approval
Husbandry animal trials are set to start with a third-party preclinical contract research organization (CRO)
The agreement to apply Quicksome technology to mushroom neutraceutical products includes ongoing product royalties and an initial payment of C$250,000
CEO Dennis Hancock said it was “critical” to look at the new South African variant given the complexities of vaccine rollout and the high probability that current vaccines may not be effective against emerging mutations
The move marks another step toward achieving the global eradication of polio, the biotech said
The company said the study is designed to prove the superiority of its solubilized Ivermectin technology versus a commercially available oral form in speed and efficacy of viral clearance
Adjuvants improve the immune response of a vaccine, enabling vaccines to produce more antibodies and achieve longer-lasting immunity, thus allowing for lower dosage
The company's patented Quicksome liposome technology utilizes an advanced two-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats
The listing of its common shares on the OTCQB, a platform operated by OTC Markets Group, remains subject to the exchange's approval and satisfaction of applicable listing requirements
The company said it has completed the previously announced transaction to sell its wholly-owned subsidiary, Mountain Valley Medicinals Inc. and its related assets for the amount of C$1,000,000, made up of a combination of cash and a 9% equi
